Reata Pharma (RETA): 123% PT Increase - Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Reata Pharma (RETA) Prices 3.25M Class A Common Offering at $31/Sh
July 27, 2017 5:44 AM EDTReata Pharmaceuticals, Inc. (NASDAQ: RETA) today announced the pricing of an underwritten public offering of 3,250,000 shares of its Class A common stock at a price to the public of $31.00 per share. The gross proceeds to Reata from the offering, before deducting underwriting... More
Reata Pharmaceuticals (RETA) PT Raised to $61 at Ladenburg Thalmann
July 26, 2017 5:19 AM EDTLadenburg Thalmann raised its price target on Reata Pharmaceuticals (NASDAQ: RETA) to $61.00 (from $55.00) while maintaining a Buy rating.
Analyst Matt Kaplan comments "We are impressed with the interim CARDINAL Phase 2 results which demonstrated a dramatic improvement in kidney function in Alport... More
